Reactive metabolite of trovafloxacin activates inflammasomes: Implications for trovafloxacin‐induced liver injury

Abstract

AbstractTrovafloxacin is a quinolone antibiotic drug with broad‐spectrum activity, which was withdrawn from a global market relatively soon after approval because of serious liver injury. The characteristics of trovafloxacin‐induced liver injury are consistent with an idiosyncratic reaction; however, the details of the mechanism have not been elucidated. We examined whether trovafloxacin induces the release of damage‐associated molecular patterns (DAMPs) that activate inflammasomes. We also tested ciprofloxacin, levofloxacin, gatifloxacin, and grepafloxacin for their ability to activate inflammasomes. Drug bioactivation was performed with human hepatocarcinoma functional liver cell‐4 (FLC‐4) cells, and THP‐1 cells (human monocyte cell line) were used for the detection of inflammasome activation. The supernatant from the incubation of trovafloxacin with FLC‐4 cells for 7 days increased caspase‐1 activity and production of IL‐1ß by THP‐1 cells. In the supernatant of FLC‐4 cells that had been incubated with trovafloxacin, heat shock protein (HSP) 40 was significantly increased. Addition of a cytochrome P450 inhibitor to the FLC‐4 cells prevented the release of HSP40 from the FLC‐4 cells and inflammasome activation in THP‐1 cells by the FLC‐4 supernatant. These results suggest that reactive metabolites of trovafloxacin can cause the release of DAMPs from hepatocytes that can activate inflammasomes. Inflammasome activation may be an important step in the activation of the immune system by trovafloxacin, which, in some patients, can cause immune‐related liver injury.